论文部分内容阅读
为探讨肾舒Ⅱ号(主药:生黄芪、当归、川芎、赤芍药、红花 )治疗肾病综合证 (NS)的疗效和机理,Wistar按Bertani法造模后,分别给予肾舒Ⅱ号、肾舒Ⅱ号+激素、激素+潘生丁治疗,连续 3周。观察各组大鼠生存质量、生存率、血浆蛋白、肾功能、GMP-140、D 二聚体,以及肾组织病理的变化。结果:肾舒Ⅱ号能降低NS模型鼠 24h尿蛋白量、升高模型鼠TP、ALB,降低模型鼠TG、CHOL,和GMP-140、D 二聚体含量,改善模型鼠肾组织变化,减轻肾小球细胞足突的融合;肾舒Ⅱ号+激素的疗效,优于单用肾舒Ⅱ号者,并与潘生丁合用激素的疗效相似。提示:该药对NS有较好的疗效,而减轻肾组织的病理变化是其可能的作用机理之一。
To investigate the therapeutic effect and mechanism of Renshu II (main medicines: Astragalus membranaceus, Angelica sinensis, Rhizoma Chuanxiong, Radix Paeoniae Radix, and Safflower) in treating nephrotic syndrome (NS), Wistar was given Renshu II after its model was established according to the Bertani method. Shen Shu II + Hormone, Hormone + Dipyridamole Treatment for 3 weeks. The quality of life, survival rate, plasma protein, renal function, GMP-140, D-dimer, and pathological changes of renal tissue were observed in each group. RESULTS: Renshu II could decrease the 24-hour urinary protein level in NS model mice, increase TP and ALB in model mice, decrease the content of TG, CHOL, and GMP-140, D dimer in model mice, and improve the renal tissue changes and reduce The fusion of glomerular cell foot processes; the effect of Ren Shu II + hormone is superior to that of Ren Shu II alone, and the efficacy of combination with dipyridamole is similar. Tip: The drug has a good effect on NS, and reducing the pathological changes in renal tissue is one of its possible mechanisms.